PMID: 8967711Dec 15, 1996Paper

Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment

Annals of Internal Medicine
G Schectman, J Hiatt

Abstract

To develop an optimal treatment strategy that reduces low-density lipoprotein (LDL) cholesterol levels and improves adherence to therapy by reviewing clinical trials that define the dose-response characteristics for 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), bile acid sequestrants, and niacin. Data were obtained from a MEDLINE search of the English-language literature published from 1975 through November 1995 and from an extensive bibliography review. Controlled, clinical trials were reviewed if they evaluated 1) the effectiveness and toxicity of one LDL cholesterol-lowering agent (statins, bile acid sequestrants, or niacin, at two or more doses) or 2) monotherapy with two LDL cholesterol-lowering agents at defined doses used alone and in combination. Studies that had fewer than 10 patients in a treatment group or that selected patients on the basis of previous response to therapy were not included. Trials were reviewed for overall methodology, inclusion and exclusion criteria, sources of bias, and outcomes. Dose-response relations for bile acid sequestrants and statins are nonlinear, and most of their LDL cholesterol-lowering effects can be obtained with lower doses. The few dose-response studies of ...Continue Reading

Citations

May 24, 2003·Current Diabetes Reports·Kenneth Lee Jones, Asheesh Kumar Dewan
Apr 13, 2005·Atherosclerosis. Supplements·Lawrence A Leiter
Dec 31, 2002·Journal of the American College of Cardiology·Frank M Sacks
Sep 19, 2002·British Journal of Clinical Pharmacology·Teddy KosoglouMelton B Affrime
Apr 1, 2006·Current Medical Research and Opinion·Stella S Daskalopoulou, Dimitri P Mikhailidis
Jan 17, 2012·Journal of the American College of Surgeons·Primal P SinghAndrew G Hill
Mar 6, 2012·Journal of Clinical Lipidology·Mitchell KarlJohn Brejda
Sep 8, 2009·The Journal of Nutritional Biochemistry·Michelle A Micallef, Manohar L Garg
Aug 26, 2003·Mayo Clinic Proceedings·Michael Miller
Jul 22, 2008·Metabolism: Clinical and Experimental·Wei-Jia KongJian-Dong Jiang
Aug 18, 2004·International Journal of Clinical Practice·H Schuster
Jan 29, 2000·American Heart Journal·V BittnerM L Stefanick
Nov 18, 2005·The American Journal of Cardiology·Kevin C MakiMichael H Davidson
Mar 15, 2015·European Journal of Internal Medicine·A VodonosV Novack
Sep 30, 2003·Diabetes Care·Jeffrey S StroupRobert S Busch
Mar 7, 2018·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Nov 22, 2014·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Nov 19, 2003·Pharmacotherapy·Edith A Nutescu, Nancy L Shapiro
Jul 23, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Thierry ClaudelFolkert Kuipers
Apr 15, 2000·Risk Analysis : an Official Publication of the Society for Risk Analysis·D HattisD E Burmaster
Mar 11, 2008·Expert Review of Cardiovascular Therapy·Susanne H Meeuwisse-PasterkampBruce H R Wolffenbuttel
Jan 26, 2020·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Jul 12, 2005·QJM : Monthly Journal of the Association of Physicians·H T Ong
Nov 21, 2002·Heart Disease·Eric K Gupta, Matthew K Ito
Jun 20, 2020·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Mar 16, 2007·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Shannon M RiversRobert A Hamilton
Feb 7, 2021·Archives of Biochemistry and Biophysics·Mariela L Paz, Francisco J Barrantes
Feb 19, 2002·The Annals of Pharmacotherapy·Megan C DuncanDaniel S Streetman

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.